WuXi AppTec's stock price hit a record high last week, doubling its January level, despite the U.S. Pentagon listing it as a Chinese military company, which could lead some American clients to withdraw business. Investors continue to pour in, betting on the company's core position in the global supply of obesity, cancer, and other drugs. Previously, WuXi AppTec's first-half results exceeded analysts' expectations and it significantly raised its full-year guidance. It also obtained a preliminary injunction against the Pentagon's accusations, which investors generally interpreted as a positive sign.